Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Entera Bio
(NASDAQ:ENTX)
Intraday
$2.06
-0.03
[-1.44%]
After-Hours
$2.06
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.06
-0.03
[-1.44%]
At close: May 3
$2.06
0
[0.00%]
After Hours: 5:51PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Entera Bio Stock (NASDAQ:ENTX)
Entera Bio Stock (NASDAQ: ENTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 08, 2024
Entera Bio Announces Publication Of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data I1n The Journal Of Bone And Mineral Research
Benzinga Newsdesk
-
Apr 8, 2024, 8:33AM
Tuesday, April 02, 2024
HC Wainwright & Co. Maintains Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Apr 2, 2024, 8:54AM
Tuesday, March 26, 2024
Entera Bio Announces Key Regulatory Milestone For Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling On Qualifying BMD As A Surrogate Endpoint For Osteoporosis Drugs is Expected Within 10 Months
Happy Mohamed
-
Mar 26, 2024, 8:33AM
Wednesday, March 20, 2024
Entera Bio Announces Pharmacokinetic Data For Oral GLP-2 Peptide Tablet Treatment For Patients With Short Bowel Syndrome; Says 'The study's objectives were met with oral GLP-2 tablets exhibiting significant systemic exposure.'
Benzinga Newsdesk
-
Mar 20, 2024, 8:03AM
Friday, March 08, 2024
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
Benzinga Newsdesk
-
Mar 8, 2024, 4:17PM
Monday, March 04, 2024
Entera Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
Benzinga Newsdesk
-
Mar 4, 2024, 8:47AM
Friday, January 12, 2024
Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying
Avi Kapoor
-
Jan 12, 2024, 7:48AM
Wednesday, January 03, 2024
Entera Bio Announced That It Received An Extension Of 180 Calendar Days From The Nasdaq Stock Market To Regain Compliance
Benzinga Newsdesk
-
Jan 3, 2024, 8:49AM
Monday, December 11, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Dec 11, 2023, 6:42AM
Wednesday, November 29, 2023
Interim Results From Ongoing Clinical Study Confirm EB613 Optimized Profile For Osteoporosis Treatment And Potential For Entera's Next Generation Oral Peptide Platform
Benzinga Newsdesk
-
Nov 29, 2023, 8:33AM
Monday, October 16, 2023
Entera Bio Reports Rapid Pharmacodynamic Response And Consistent Pharmacokinetic Data For Its First-In-Class Oral PTH(1-34) Mini Tablets At The ASBMR 2023 Annual Meeting
Benzinga Newsdesk
-
Oct 16, 2023, 8:20AM
Wednesday, September 13, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Sep 13, 2023, 6:33AM
Tuesday, September 12, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Benzinga Newsdesk
-
Sep 12, 2023, 8:32AM
Monday, September 11, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Sep 11, 2023, 6:32AM
Wednesday, August 23, 2023
Bioventus And 3 Other Stocks Under $5 Insiders Are Buying
Lisa Levin
-
Aug 23, 2023, 9:23AM
Wednesday, August 16, 2023
Entera Bio To Present Two Abstracts On Its Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) For The Treatment Of Post-Menopausal Women At High Risk Of Fracture At The American Society For Bone And Mineral Research Annual Meeting
Benzinga Newsdesk
-
Aug 16, 2023, 8:35AM
Monday, May 08, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
May 8, 2023, 6:28AM
Friday, May 05, 2023
Entera Bio: Q1 Earnings Insights
Benzinga Insights
-
May 5, 2023, 4:10PM
Entera Bio Q1 EPS $(0.08) Beats $(0.12) Estimate
Benzinga Newsdesk
-
May 5, 2023, 4:07PM
Tuesday, April 04, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Apr 4, 2023, 6:42AM
Monday, April 03, 2023
Reported Earlier, Entera Bio Provides Guidance From FDA Type D Meeting Related To EB613 Pivotal Program
Happy Mohamed
-
Apr 3, 2023, 8:18AM
Tuesday, March 28, 2023
HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target
Benzinga Newsdesk
-
Mar 28, 2023, 6:29AM
Thursday, March 23, 2023
Entera Bio Regains Compliance With Nasdaq Listing Requirements
Happy Mohamed
-
Mar 23, 2023, 9:48AM
Tuesday, March 07, 2023
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Mar 7, 2023, 1:02PM
Why Adial Pharmaceuticals Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Mar 7, 2023, 7:51AM
Monday, March 06, 2023
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Mar 6, 2023, 1:25PM
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Mar 6, 2023, 7:54AM
Wednesday, February 15, 2023
Entera Bio Announces FDA's Acceptance Of A Type D Meeting Review To Affirm Design Of The Pivotal, Phase 3 Protocol For EB613 PTH Mini Tablets, As The First Oral Osteoanabolic Treatment Of Post-Menopausal Osteoporosis
Happy Mohamed
-
Feb 15, 2023, 10:01AM
Wednesday, January 04, 2023
Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jan 4, 2023, 7:59AM
Thursday, November 17, 2022
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Lisa Levin
-
Nov 17, 2022, 5:07AM
Wednesday, November 16, 2022
Entera Bio And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
Lisa Levin
-
Nov 16, 2022, 7:02AM
Monday, November 14, 2022
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Lisa Levin
-
Nov 14, 2022, 2:35AM
Friday, November 11, 2022
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Nov 11, 2022, 12:48PM
Monday, October 24, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 24, 2022, 11:41AM
Monday, October 17, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 17, 2022, 11:32AM
Friday, October 14, 2022
121 Stocks That Hit Their 52-Week Low
Benzinga Insights
-
Oct 14, 2022, 11:49AM
Wednesday, October 12, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 12, 2022, 1:32PM
Monday, October 10, 2022
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Lisa Levin
-
Oct 10, 2022, 7:33AM
Thursday, October 06, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Oct 6, 2022, 2:41PM
Entera Bio Announces FDA Agreement For A Single Phase 3 Clinical Trial To Support An NDA For EB613 For The Treatment Of Osteoporosis
Benzinga Newsdesk
-
Oct 6, 2022, 7:10AM
Monday, October 03, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 3, 2022, 1:37PM
Thursday, September 29, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 29, 2022, 1:32PM
Wednesday, September 28, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 28, 2022, 12:40PM
Thursday, September 22, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 22, 2022, 2:17PM
Monday, September 12, 2022
Entera Bio Presents Dose Proportional Absorption And Correlation To BMD Clinical Response Data From Its Phase 2 Study Of EB613 In Post-Menopausal Osteoporosis Patients At The ASBMR 2022 Annual Meeting
Benzinga Newsdesk
-
Sep 12, 2022, 6:33AM
Wednesday, September 07, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 7, 2022, 1:08PM
Tuesday, September 06, 2022
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Benzinga Insights
-
Sep 6, 2022, 10:09AM
HC Wainwright & Co. Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk
-
Sep 6, 2022, 6:11AM
Thursday, August 11, 2022
Entera Bio: Q2 Earnings Insights
Benzinga Insights
-
Aug 11, 2022, 9:43AM
Entera Bio Q2 EPS $(0.24) Down From $(0.20) YoY
Bill Haddad
-
Aug 11, 2022, 6:43AM
Show more
